[
    [
        {
            "time": "2020-10-15",
            "original_text": "智飞生物：业绩超预期 自主与代理产品保持良好增长态势",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩超预期",
                    "自主产品",
                    "代理产品",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：业绩超预期 自主与代理产品保持良好增长态势",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-16",
            "original_text": "【天风医药】智飞生物：三季报业绩超预期，自有大品种开启发展阶段",
            "features": {
                "keywords": [
                    "智飞生物",
                    "三季报",
                    "业绩超预期",
                    "自有大品种",
                    "发展新阶段"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药】智飞生物：三季报业绩超预期，自有大品种开启发展阶段",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-17",
            "original_text": "上市渝企智飞生物率先递卷！前三季度净赚24.79亿元 新冠疫苗年产能有望达3亿剂",
            "features": {
                "keywords": [
                    "智飞生物",
                    "前三季度",
                    "净赚",
                    "新冠疫苗",
                    "年产能"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上市渝企智飞生物率先递卷！前三季度净赚24.79亿元 新冠疫苗年产能有望达3亿剂",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-10-18",
            "original_text": "智飞生物3季度报新鲜出炉，代理疫苗与自主研发孰强孰弱？",
            "features": {
                "keywords": [
                    "智飞生物",
                    "三季报",
                    "代理疫苗",
                    "自主研发"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智飞生物3季度报新鲜出炉，代理疫苗与自主研发孰强孰弱？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-19",
            "original_text": "医药行业2020年1-9月疫苗批签发：流感疫苗大幅增加 创新疫苗继续高速增长",
            "features": {
                "keywords": [
                    "医药行业",
                    "疫苗批签发",
                    "流感疫苗",
                    "创新疫苗",
                    "高速增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2020年1-9月疫苗批签发：流感疫苗大幅增加 创新疫苗继续高速增长",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-20",
            "original_text": "智飞生物：代理产品强势增长 自主产品逐步回暖",
            "features": {
                "keywords": [
                    "智飞生物",
                    "代理产品",
                    "自主产品",
                    "增长",
                    "回暖"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：代理产品强势增长 自主产品逐步回暖",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-21",
            "original_text": "智飞生物2020三季报点评：Q3收入增长超预期 产品维持高景气度",
            "features": {
                "keywords": [
                    "智飞生物",
                    "三季报",
                    "Q3收入",
                    "增长超预期",
                    "高景气度"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物2020三季报点评：Q3收入增长超预期 产品维持高景气度",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-22",
            "original_text": "前三季净利同比增40.59%，‘疫苗一哥’智飞生物市值超2500亿！",
            "features": {
                "keywords": [
                    "智飞生物",
                    "前三季",
                    "净利",
                    "同比增",
                    "市值"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "前三季净利同比增40.59%，‘疫苗一哥’智飞生物市值超2500亿！",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-10-23",
            "original_text": "【财报智读】智飞生物：2020年前三季度营业总收入110.5亿元，归母净利润24.79亿元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "财报",
                    "营业总收入",
                    "归母净利润"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【财报智读】智飞生物：2020年前三季度营业总收入110.5亿元，归母净利润24.79亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-24",
            "original_text": "智飞生物一度涨4% 三季度净利润同比增58.13%",
            "features": {
                "keywords": [
                    "智飞生物",
                    "涨",
                    "三季度",
                    "净利润",
                    "同比增"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物一度涨4% 三季度净利润同比增58.13%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]